Fluid Test Markers in Patients with Soft Tissue Sarcoma
Studies lung fluid samples from soft tissue sarcoma patients to look for markers of spread.
Plain-language title generated from the registry record
Registry title: BAL Fluid Biomarkers in Sarcoma
Key facts
- Where
- Toronto, CanadaSee the site
- Phase
- Phase 2
Where in Canada
- Radiation Medicine Program, Princess Margaret Cancer Centre, University Health NetworkToronto, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Health Network, Toronto
- Trial code
- NCT06815666
- Record updated
- 4 March 2026
- Original description
This is a single-centre, Phase II, prospective study designed to assess BALF and TA-derived biomarkers in relation to metastatic burden in STS patients. BALF and TA samples will be collected during routine bronchoscopy performed as part of standard care at Toronto General Hospital (TGH). Additionally, tissue samples of lung metastases and adjacent normal lung will be collected and used to correlate the identified biomarkers.Read full original descriptionShow less
Prospective Study of Biomarkers Derived From Bronchoalveolar Lavage Fluid to Predict Outcomes in Soft-Tissue Sarcomas
This is a single-centre, Phase II, prospective study designed to assess BALF and TA-derived biomarkers in relation to metastatic burden in STS patients. BALF and TA samples will be collected during routine bronchoscopy performed as part of standard care at Toronto General Hospital (TGH). Additionally, tissue samples of lung metastases and adjacent normal lung will be collected and used to correlate the identified biomarkers.
Inclusion: Age ≥ 18 years; Ability to understand and willingness to sign a written informed consent document; Diagnosed with soft tissue sarcoma; Undergoing resection of lung lesion as part of standard care.
Exclusion: History of another invasive malignancy, except for non-melanoma skin cancer or tumors curatively treated with no evidence of disease for ≥ 2 years.